Table 2.
Ranking of Drugs Across Outcomes Based on a Subset of Regimens for Which at Least 2 of the Early Bactericidal Activity Results Were Available
| Ranking and No. of Patients (No. of Regimens) | ||||
|---|---|---|---|---|
| Drug Combinationsa | EBA0–2 | EBA0–7 | EBA0–14 | 2 Months |
| H | 1 149 (16) |
1 36 (4) |
… | 3 533 (6) |
| HRZE | 2 51 (6) |
4 21 (2) |
2 50 (6) |
1 1618 (8) |
| PaMZ | 3 15 (1) |
3 12 (1) |
1 13 (1) |
… |
| R | 4 28 (3) |
2 13 (1) |
… | 2 77 (2) |
| PaZ | 5 15 (1) |
5 14 (1) |
3 14 (1) |
… |
| Pa | 6 29 (2) |
… | 6 26 (2) |
… |
| JPa | 7 14 (1) |
6 14 (1) |
5 14 (1) |
… |
| JZ | 8 15 (1) |
7 15 (1) |
4 15 (1) |
… |
| J | 9 41 (3) |
8 26 (2) |
7 28 (2) |
… |
Abbreviations: EBA0–2, early bactericidal activity over 2 days; EBA0–7, early bactericidal activity over 7 days; EBA0–14, early bactericidal activity over 14 days.
aDrug abbreviations: E, ethambutol; H, isoniazid; J, bedaquiline; M, moxifloxacin; Pa, PA-824/pretomanid; R, rifampicin; Z, pyrazinamide.